Survival and severity in dominant cerebellar ataxias

Annals of Clinical and Translational Neurology

Volumn 2, Issue 2, 2015, Pages 202-207

  Monin, Marie Lorraine ^a,b   Tezenas du Montcel, Sophie ^a,b   Marelli, Cecilia ^b,c   Cazeneuve, Cecile ^a   Charles, Perrine ^a   Tallaksen, Chantal ^d,e   Forlani, Sylvie ^b   Stevanin, Giovanni ^b,f   Brice, Alexis ^a,b   Durr, Alexandra ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

POLYGLUTAMINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CAUSE OF DEATH; CEREBELLAR ATAXIA; CHILD; DISEASE SEVERITY; GENETIC COUNSELING; HUMAN; INFANT; MAJOR CLINICAL STUDY; MUTATION; ONSET AGE; PRIORITY JOURNAL; SURVIVAL RATE; WALKING;

EID: 84942499908     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.156     Document Type: Article

References (18)

1. Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol 2010;9:885–894.
2. Klockgether T. Handbook of ataxia disorders. New York: CRC Press, 2000.
3. Jacobi H, Bauer P, Giunti P, et al. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology 2011;77:1035–1041.
4. Tezenas du Montcel S, Charles P, Goizet C, et al. Factors influencing disease progression in autosomal dominant cerebellar ataxia and spastic paraplegia. Arch Neurol. 2012;69:500–508.
5. Di Gregorio E, Borroni B, Giorgio E, et al. ELOVL5 mutations cause Spinocerebellar Ataxia 38. Am J Hum Genet 2014;95:209–217.
6. Klockgether T, Lüdtke R, Kramer B, et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain J Neurol 1998;121(Pt 4):589–600.
7. Kieling C, Prestes PR, Saraiva-Pereira ML, Jardim LB. Survival estimates for patients with Machado-Joseph disease (SCA3). Clin Genet 2007;72:543–545.
8. Ji J, Sundquist K, Sundquist J. Cancer incidence in patients with polyglutamine diseases: a population-based study in Sweden. Lancet Oncol 2012;13:642–648.
9. Juvonen V, Hietala M, Kairisto V, Savontaus M-L. The occurrence of dominant spinocerebellar ataxias among 251 Finnish ataxia patients and the role of predisposing large normal alleles in a genetically isolated population. Acta Neurol Scand 2005;111:154–162.
10. Schmitz-Hübsch T, Coudert M, Bauer P, et al. Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology 2008;71:982–989.
11. Reetz K, Lencer R, Hagenah JM, et al. Structural changes associated with progression of motor deficits in spinocerebellar ataxia 17. Cerebellum 2010;9:210–217.
12. Goldfarb LG, Vasconcelos O, Platonov FA, et al. Unstable triplet repeat and phenotypic variability of spinocerebellar ataxia type 1. Ann Neurol 1996;39:500–506.
13. Dürr A, Smadja D, Cancel G, et al. Autosomal dominant cerebellar ataxia type I in Martinique (French West Indies). Clinical and neuropathological analysis of 53 patients from three unrelated SCA2 families. Brain J Neurol. 1995;118 (Pt 6):1573–1581.
14. Rosenberg RN. Machado-Joseph disease: an autosomal dominant motor system degeneration. Mov Disord 1992;7:193–203.
15. Globas C, du Montcel ST, Baliko L, et al. Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6. Mov Disord 2008;23:2232–2238.
16. Van de Warrenburg BPC, Sinke RJ, Verschuuren-Bemelmans CC, et al. Spinocerebellar ataxias in the Netherlands: prevalence and age at onset variance analysis. Neurology 2002;58:702–708.
17. Schulz JB, Borkert J, Wolf S, et al. Visualization, quantification and correlation of brain atrophy with clinical symptoms in spinocerebellar ataxia types 1, 3 and 6. NeuroImage 2010;49:158–168.
18. Jacobi H, Reetz K, du Montcel ST, et al. Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol 2013;12:650–658.